In the context of anti-tumor immunity, cancer-derived cGAMP or cancer-derived DNA have been shown to activate dendritic cells and macrophages, which in turn respond by producing type I IFN to enhance CD8+ T cell anti-tumor activity (88–90). The gene discussed is CD8A; the disease is neoplasm.